Hemorheological changes and overproduction of cytokines from immune cells in mild to moderate dementia of the Alzheimer's type: Adverse effects on cerebromicrovascular system

Neurobiology of Aging

Volumn 21, Issue 2, 2000, Pages 271-281

  Solerte, S B ^a   Ceresini, G ^b   Ferrari, E ^a   Fioravanti, M ^a  

^a Geriat Gerontology Clin Sch G   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Acute phase proteins; Aging; Alzheimer's disease; Cerebrovascular disease; Cytokines; Dementia; Fibrinogen; Hemorheology; Immunity; Interferon ; Interleukin 2 (IL 2); Natural killer cells; Pentoxifylline; Tumor necrosis factor (TNF)

Indexed keywords

ACUTE PHASE PROTEIN; CYTOKINE; FIBRINOGEN; GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; AGING; ALZHEIMER DISEASE; BLOOD RHEOLOGY; BLOOD VISCOSITY; BRAIN BLOOD VESSEL; BRAIN CAPILLARY; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DEMENTIA; ERYTHROCYTE AGGREGATION; ERYTHROCYTE DEFORMABILITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MALE; MICROVASCULATURE; MULTIINFARCT DEMENTIA; NATURAL KILLER CELL; NERVE DEGENERATION; PRIORITY JOURNAL;

AGED; AGING; ALZHEIMER DISEASE; BLOOD VISCOSITY; CEREBROVASCULAR CIRCULATION; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE DEFORMABILITY; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; KILLER CELLS, NATURAL; MALE; MICROCIRCULATION; RHEOLOGY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034603510     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(00)00105-6     Document Type: Conference Paper

References (65)

1. Ajmani R.S., Rifkind J.M. Hemorheology changes during human aging. Gerontology. 44:1998;111-120.
2. Diagnostic and Statistical Manual fo Mental Disorders. 3rd edn, revised. 1987;American Psychiatric Association, Washington DC.
3. Anegon I., Cuturi M.C., Trinchieri G., Perussia B. Interaction of Fc receptor (CD16) with ligands induces transcription of IL-2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J Exp Med. 167:1988;452-472.
4. Aviado D.M., Dettelbach H.R. Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication. Angiology. 35:1984;407-417.
5. Belayev L., Busto R., Zhao W., Ginsberg M.D. Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res. 739:1996;88-96.
6. Blasko I., Marx F., Steiner F., Hartman T., Grubeck-Loebenstein B. TNFα plus IFNγ induce the production of Alzheimer β-amyloid peptides and decrease the secretion of APPs. FASEB J. 13:1999;63-68.
7. Brown M.M., Marshall J. Regulation of cerebral blood flow in response to changes in blood viscosity. Lancet. i:1985;604-609.
8. Buèe L., Hof P.R., Delacourte A. Brain microvascular changes in Alzheimer's disease and other dementia's. Ann NY Acad Sci. 826:1997;7-24.
9. Cuturi M.C., Anegon I., Sherman F., et al. Production of hematopoietic colony-stimulating factor by human natural killer cells. J Exp Med. 169:1989;569-583.
10. Dawson D.A., Martin D., Hallenbeck J.M. Inhibition of TNF-alpha reduces focal cerebral ischemic injury in the spontaneously hypertensive rat. Neurosci Lett. 218:1996;41-44.
11. de la Torre J.C. Cerebromicrovascular pathology in Alzheimer's disease compared to normal aging. Gerontology. 43:1997;26-43.
12. de la Torre J.C. Impaired brain microcirculation may trigger Alzheimer's disease. Neurosci Behav Res. 18:1994;397-401.
13. de la Torre J.C., Mussivand T. Can disturbed brain microcirculation cause Alzheimer' disease? Neurol Res. 15:1993;146-153.
14. Dickinson D.W., Rogers J. Neuroimmunology of Alzheimer's disease a conference report . Neurobiol Aging. 13:1992;793-798.
15. Dintenfass L. Viscosity factors in hypertensive and cardiovascular disease. Cardiovasc Med. 2:1977;337-357.
16. Dintenfass L. Some rheological factors in pathogenesis of thrombosis. Lancet. ii:1965;370-371.
17. Dormandy J.A. Haemorheological aspects of thrombosis. Br J Haematol. 45:1980;519-522.
18. Ferrucci L., Guralnik J.M., Salive M.E., et al. Cognitive impairment and risk of stroke in the older population. J Am Geriatr Soc. 44:1996;237-241.
19. Fiala M., Zhang L., Gan X., et al. Amyloid-β induces chemokine secretion and monocyte migration across a blood-brain barrier model. Mol Med. 4:1998;480-489.
20. Fioravanti M., Ricciardi T., Cottinelli M., et al. Hemorheologic alterations and acute-phase reaction are related to recently-onset patients with senile dementia of the Alzheimer's type (SDAT). Neurobiol Aging. 19:1998;S246-S247.
21. Folstein M., Folstein S., McHugh P.R. Mini Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12:1975;189-198.
22. Gale C.R., Martyn C.N., Cooper C. Cognitive impairment and mortality in a cohort of elderly people. Br Med J. ii:1996;608-611.
23. Gasparini L., Racchi M., Binetti G., et al. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease. FASEB J. 12:1998;17-34.
24. Hachinski V.C., Lassen N.A., Marshall J. Multiinfarct dementia a cause of mental deterioration in the elderly . Lancet. ii:1974;207-210.
25. Hardy J.A., Mann D.M.A., Wester P., Winblad B. An integrative hypothesis concerning the pathogenesis and progression of Alzheimer's disease. Neurobiol Aging. 7:1986;489-502.
26. Henderson A.S. The risk factors for AD a review and a hypothesis . Acta Psychiatr Scand. 78:1998;257-275.
27. Hofman A., Breteler M.M.B., Bots M.L., et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease. The Rotterdam Study. Lancet. i:1997;151-154.
28. Hoyer S. Abnormalities of glucose metabolism in Alzheimer's disease. Ann NY Acad Sci. 640:1991;53-58.
29. Huberman M., Shalit F., Roth-Deri I., et al. Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J Neuroimmunol. 52:1994;147-152.
30. Guidelines for measurement of blood viscosity and erythrocyte deformability. Clin Hemorheol. 6:1986;439-453.
31. Jewett A., Bonavida B. Pivotal role of endogenous TNF-α in the IL-2 driven activation and proliferation of the functionally immune NK "free" subset. Cell Immunol. 151:1993;257-263.
32. Kalaria R.N., Harik S.I. Reduced glucose transporter at the blood-brain barrier in cerebral cortex in Alzheimer's disease. J Neurochem. 53:1989;1083-1088.
33. Liang L., Beshay E., Prud'homme G.J. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. Diabetes. 47:1998;570-575.
34. Lighthart G.J., Corberand J.X., Fournier C., et al. Admission criteria for immunogerontological studies in man the SENIEUR protocol . Mech Ageing Dev. 28:1984;47-55.
35. Lowe G.D.O., Forbes C.D. Blood rheology and thrombosis. Clin Haematol. 10:1981;343-367.
36. Marcus D.L., de Leon M., Goldman J., et al. Altered glucose metabolism in microvessels from patients with Alzheimer's disease. Ann Neurol. 26:1989;91-94.
37. McGeer P.L., McGeer E.G. The inflammatory response system of the brain implications for therapy of Alzheimer and other neurodegenerative diseases . Brain Res Rev. 21:1995;195-218.
38. McGeer P.L., Rogers J., McGeer E.G. Neuroimmune mechanisms in Alzheimer's disease pathogenesis. Alzheimer Dis Assoc Disord. 8:1994;149-158.
39. Mckhann G., Drachman D., Folstein M., Katzmann R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease report of the NINCDS-ADRDA Workgroup under the auspices of Department of Healthy and Human Services Task Force on Alzheimer's disease . Neurology. 34:1984;939-944.
40. Meier-Ruge W., Bertoni-Freddari C., Iwangoff P. Changes in brain glucose metabolism as a key to the pathogenesis of Alzheimer's disease. Gerontology. 40:1994;246-252.
41. Muller R. Hemorheology and peripheral vascular diseases a new therapeutic approach . J Med. 12:1981;209-236.
42. Munoz-Fernandez M.A., Fresno M. The role of TNF, interleukin 6, interferon-γ and inducible nitric oxide synthase in the development and pathology of the nervous system. Progr Neurobiol. 56:1998;307-340.
43. Munro J.M., Cotran R.S. The pathogenesis of atherosclerosis atherogenesis and inflammation . Lab Invest. 58:1988;249-261.
44. Ott A., Breteler M.M.B., de Bruyne M.C., Van Harskamp F., Grobbee D.E., Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke. 28:1997;316-321.
45. Petito C.K. Early and late mechanisms of increased vascular permeability following experimental cerebral infarction. J Neuropathol Exp Neurol. 38:1979;222-234.
46. Platell M., Teisser E., Cecchelli R. Hypoxia dramatically increases the non specific transport of blood-borne proteins to the brain. J Neurochem. 68:1997;874-877.
47. Reid H., Barnes A.J., Lock P.I., Dormandy J.A. A simple method for measuring erythrocyte deformability. J Clin Pathol. 29:1976;855-858.
48. Roman G.C., Tatemichi T.K., Erkinjuntti T., et al. Vascular dementia diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop . Neurology. 43:1993;250-260.
49. Schmid Schonbein H.-H. Microrheology of erythrocytes, blood viscosity and the distribution of blood flow in the microcirculation. Int Rev Physiol. 9:1976;1-62.
50. Singh V.K. Neuroautoimmunity pathogenetic implications for Alzheimer's disease . Gerontology. 43:1997;79-94.
51. Solerte S.B., Cerutti N., Severgnini S., Rondanelli M., Ferrari E., Fioravanti M. Decreased immunosuppressive effect of cortisol on natural killer cytotoxic activity in senile dementia of the Alzheimer's type. Dement Geriatr Cogn Disord. 9:1998;149-156.
52. Solerte S.B., Fioravanti M., Cerutti N., et al. Retrospective analysis of long-term hemorheologic effects of pentoxifylline in diabetic patients with angiopathic complications. Acta Diabetol. 34:1997;67-74.
53. Solerte S.B., Fioravanti M., Pascale A., Ferrari E., Govoni S., Battaini F. Increased natural killer cell cytotoxicity in Alzheimer's disease may involve protein kinase C dysregulation. Neurobiol Aging. 19:1998;191-199.
54. Solerte S.B., Fioravanti M., Rondanelli M., Ferrari E. Pentoxifylline reduces the spontaneous and IL-2 mediated reactivity of natural killer cell compartment in senile dementia of the Alzheimer's type (SDAT). Neurobiol Aging. 19:1998;S178-S179.
55. Solerte S.B., Fioravanti M., Severgnini S., Cerutti N., Locatelli M., Ferrari E. Variability of natural killer (NK) cell immune function in normal aging and senile dementia pathophysiological implications . Aging Clin Exp Res. 9:1997;32-33.
56. Solerte S.B., Fioravanti M., Severgnini S., et al. Excitatory pattern of γ-interferon on natural killer cell activity in senile dementia of the Alzheimer's type. Dement Geriatr Cogn Disord. 8:1997;308-313.
57. Solerte S.B., Fioravanti M., Severgnini S., et al. Enhanced cytotoxic response of natural killer cells to IL-2 in Alzheimer's disease. Dementia. 7:1996;343-348.
58. Solerte S.B., Locatelli M., Pezza N., et al. Haemorheology and cerebrovascular disease in aging. Retrospective analysis of associated risk factors. Facts Res Gerontol. S:1996;7-22.
59. Solerte S.B., Fioravanti M., Schifino N., et al. Dehydroepiandrosterone sulfate decreases the IL-2-mediated overactivity of the natural killer cell compartment in senile dementia of the Alzheimer type. Dement Geriatr Cogn Disord. 10:1999;21-27.
60. Stewart R. Cardiovascular factors in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 65:1998;143-147.
61. Strieter R.M., Remick D.G., Ward P.A., Splenger R.N. Cellular and molecular regulation of TNF-alpha production by pentoxifylline. Biomed Biochem Res Commun. 155:1988;1230-1236.
62. Trigoe R., Hayashi T., Anegawa S., et al. Effect of propentofylline and pentoxifylline on cerebral blood flow using 133I-IMP SPECT in patients with cerebral arteriosclerosis. Clin Ther. 16:1994;65-73.
63. Toung T.J., Kirsch J.R., Maruki Y., Traystman R.J. Effects of pentoxifylline on cerebral blood flow, metabolism and evoked response after total cerebral ischemia in dogs. Crit Care Med. 22:1994;273-281.
64. Trinchieri G. Biology of natural killer cells. Adv Immunol. 47:1989;187-386.
65. Wenham P.R., Price W.H., Blundell G. Apolipoprotein E genotyping by one-stage PCR. Lancet. ii:1991;1158-1159.